TherapeuticsMD (TXMD) Gross Profit (2011 - 2023)

TherapeuticsMD has reported Gross Profit for 13 years, with the latest figure at $502000.0 in Q4 2023.

• For the quarter ending Q4 2023, Gross Profit fell 99.27% year-over-year to $502000.0; the trailing twelve-month figure through Dec 2023 stood at $1.3 million (down 98.43% YoY), and the FY2023 full-year result was $1.3 million, down 98.1% from the prior year.
• Gross Profit for Q4 2023 stood at $502000.0, up from -$53000.0 in the prior quarter.
• The five-year high for Gross Profit was $68.6 million in Q4 2022, with the low at -$53000.0 in Q3 2023.
• Historically, Gross Profit has averaged $13.6 million across 5 years, with a median of $13.5 million in 2019.
• Annual changes were most pronounced in 2019 — Gross Profit surged 702.7% — and 2023, when it slumped 99.27%.
• TherapeuticsMD's Gross Profit stood at $13.0 million in 2019, then jumped by 30.52% to $17.0 million in 2020, then declined by 17.98% to $13.9 million in 2021, then surged by 391.83% to $68.6 million in 2022, then tumbled by 99.27% to $502000.0 in 2023.
• The last three Gross Profit figures came in at $502000.0 (Q4 2023), -$53000.0 (Q3 2023), and $437000.0 (Q2 2023), per Business Quant data.